Akcea and Ambry Genetics to Launch hATTR Compass, a Genetic Testing Program for People with Suspected Hereditary ATTR Amyloidosis
June 12, 2018 07:45 ET
|
Akcea Therapeutics, Inc.
CAMBRIDGE, Mass., June 12, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ambry Genetics Corporation (“Ambry”), a Konica Minolta...
Akcea Therapeutics Appoints Industry Leader Dr. Richard Moscicki to Board of Directors
June 05, 2018 16:05 ET
|
Akcea Therapeutics, Inc.
CAMBRIDGE, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced the appointment of Richard (Rich) A....
Akcea and Ionis Receive Positive EU CHMP Opinion for TEGSEDI
June 01, 2018 08:07 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and CARLSBAD, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
Akcea Therapeutics to Present at the Jefferies Global Healthcare Conference
May 29, 2018 07:00 ET
|
Akcea Therapeutics, Inc.
CAMBRIDGE, Mass., May 29, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.(NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that management will present a company overview...
FDA Advisory Committee Votes in Favor of WAYLIVRA for Treatment of Familial Chylomicronemia Syndrome
May 10, 2018 18:21 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and CARLSBAD, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
Akcea Reports Financial Results and Highlights for First Quarter 2018
May 03, 2018 16:05 ET
|
Akcea Therapeutics, Inc.
TTR licensing transaction positions Akcea for two rare disease drug launches in 2018 FDA extended TEGSEDITM (inotersen) PDUFA date to October 6, 2018 $445 million in pro forma cash to fund the...
Akcea Announces Expansion of Global Early Access Program to Provide Volanesorsen to People Living with FCS
May 02, 2018 07:00 ET
|
Akcea Therapeutics, Inc.
CAMBRIDGE, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA) today announced it has expanded its global early access program (EAP) to the United States for people with...
Akcea Therapeutics Announces Presentations on Volanesorsen and FCS at the National Lipid Association Scientific Sessions
April 26, 2018 16:05 ET
|
Akcea Therapeutics, Inc.
CAMBRIDGE, Mass. and LAS VEGAS, April 26, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing...
Akcea Therapeutics to Hold First Quarter 2018 Financial Results Webcast
April 26, 2018 07:00 ET
|
Akcea Therapeutics, Inc.
CAMBRIDGE, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on...
Akcea Therapeutics to Present Data on Inotersen for the Treatment of hATTR Amyloidosis at the 2018 American Academy of Neurology Annual Meeting
April 21, 2018 12:38 ET
|
Akcea Therapeutics, Inc.
CAMBRIDGE, Mass., April 21, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that data from inotersen’s clinical...